Allogene Therapeutics, Inc. (ALLO) Tops Q3 EPS by 15c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q3 EPS of ($0.37), $0.15 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $43 thousand versus the consensus estimate of $14.46 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• Accenture downgraded by TD Cowen on AI concerns